Clinical Trials Logo

Filter by:
NCT ID: NCT06431061 Active, not recruiting - Astigmatism Clinical Trials

Clinical Evaluation of Proclear Toric and Biofinity Toric

Start date: May 20, 2024
Phase: N/A
Study type: Interventional

The aim of this study is to compare the short-term clinical performance of two Toric contact lenses.

NCT ID: NCT06430294 Recruiting - Spinal Mobilization Clinical Trials

Caracteristics of Pediatric Spinal Mobilizations

Start date: March 1, 2024
Phase:
Study type: Observational

This observational study aims to create simulations using pediatric manikins to teach pediatric spinal mobilizations. We'll measure the force and duration of spinal mobilizations applied by chiropractors on pediatric manikins. Another objective is to gather feedback from both students and teachers on the effectiveness of using manikins for teaching. The main questions it aims to answer are: 1. How much force and for how long do chiropractors apply spinal mobilizations on pediatric manikins?

NCT ID: NCT06430281 Recruiting - Manual Therapy Clinical Trials

Manual Therapy Force Perception Scale

Start date: February 1, 2024
Phase:
Study type: Observational

The objective of this observational study is to pilot a scale designed to assist clinicians in evaluating the force they perceive during manual therapy. The main question it aims to answer is: - Are clinicians able to evaluate the force they use when delivering manual therapies to their patients using a scale? For the pilot test, licensed chiropractors administer manual therapies on a manikin.

NCT ID: NCT06428838 Not yet recruiting - Migraine Clinical Trials

Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context

Start date: September 30, 2024
Phase: Phase 3
Study type: Interventional

The purpose of the study is to investigate how a medication called eptinezumab (Vyepti) given to patients in the Emergency Department (ED) might help prevent migraines from happening again. The results of this study may help inform better ways to manage patients with migraines in the ED. Eptinezumab is currently approved by Health Canada for the preventive treatment of migraine, but its short-term effectiveness in the ED context is unknown. Unlike other migraine treatments used in the ED, eptinezumab can rapidly interrupt the migraine process, potentially also preventing migraine from coming back in the short term. Most patients with a diagnosis of migraine have no access to preventative therapies. This study will be able to provide access to preventative therapy at the earliest stages of a migraine attack. Administering this medication in the ED may stop the attack more effectively compared to current therapies. This study wants to see if eptinezumab could help stop migraines from coming back after individuals have been treated in the ED. The study will also explore whether eptinezumab could reduce how often individuals with migraine might need to come back to the ED, what other medications they might need alongside eptinezumab, and how they feel overall.

NCT ID: NCT06428708 Recruiting - Clinical trials for Metastatic Clear Cell Renal Cell Carcinoma

[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma

Start date: January 24, 2022
Phase: Early Phase 1
Study type: Interventional

Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be considered in order to control the majority of the disease. However, if metastases are more widespread, systemic (drug) therapy may be the preferred management option. The identification of additional metastatic sites using more sensitive imaging modalities therefore has the potential to alter management, and this remains an unmet need in the field. This study will investigate the utility of positron emission tomography (PET) imaging with PSMA (prostate specific membrane antigen). Kidney cancer of the clear cell subtype has demonstrated high expression of PSMA, making it a disease in which PSMA-targeted PET imaging could help to identify occult metastatic disease.

NCT ID: NCT06428214 Recruiting - Chin Augmentation Clinical Trials

A Restylane Treatment Algorithm Approach for Participants With Appearance of Insufficient Bone Structure in the Lower Face Alone or in Combination With Facial Soft Tissue Deficiencies

ARTIST
Start date: May 13, 2024
Phase: N/A
Study type: Interventional

The study's main purpose is to evaluate the overall aesthetic improvement of the treated areas by treatment group, as assessed by the Investigator.

NCT ID: NCT06425458 Not yet recruiting - Homelessness Clinical Trials

Transitioning Youth Out of Homelessness 2.5 (TYOH 2.5)

Start date: June 2024
Phase: N/A
Study type: Interventional

The idea for this study came from the research team's current study called Transitioning Youth Out of Homelessness (TYOH) 2.0, which provides coaching and a leadership guide to youth transitioning out of homelessness. Based on feedback from youth and coaches involved in that study, the research team plans to make small changes to the leadership guide and see if it works better as an in-person, four-week leadership program. All participants in this study will be invited to attend an in-person, four-week leadership program. There will be two programs running at the same time: one in St. Catharines and one in Toronto. The goal is to have 15 participants in each program. The main purpose of the study is to learn what participants think of the program. The second purpose is to see if there are changes in identity capital (feeling a sense of purpose and confidence in achieving goals) and knowledge about things that are covered in the program, when the research team compares participants' answers at the beginning and at the end of the program.

NCT ID: NCT06425302 Not yet recruiting - Clinical trials for Lymphoma, Follicular

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma

GOLSEEK-2
Start date: August 3, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of golcadomide in combination with rituximab in participants with newly diagnosed advanced stage Follicular Lymphoma (FL).

NCT ID: NCT06424236 Terminated - Dementia Clinical Trials

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

DIAN-TU
Start date: June 30, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.

NCT ID: NCT06423716 Not yet recruiting - Knee Osteoarthritis Clinical Trials

Effect of peRiopErative duLoxetIne Administration on Opioid Consumption Following Total kneE Arthroplasty (RELIFE)

RELIFE
Start date: May 15, 2024
Phase: Phase 4
Study type: Interventional

Knee replacement surgery for osteoarthritis is a commonly performed procedure in Canada with 75,000 of these surgeries performed each year. Success rate for knee replacement surgery is high but more than 20% of patients are still dissatisfied mainly due to reports of ongoing pain. Pain control following knee surgery is important in order to allow patients to engage in recovery and rehabilitation. The current standard of pain management after surgery centers around the use of opioids which is a concerning practice as highlighted by the opioid epidemic. Duloxetine is an antidepressant that has pain relieving properties and it has been studied in patients undergoing knee replacement surgery. Studies to date have not been designed optimally to demonstrate the full effects of opioid dose reduction and the use of duloxetine as a medication following knee replacement surgery. This research study seeks to start duloxetine before surgery, at the recommended therapeutic dose, and for the duration of the early rehabilitation period. If the study is successful, this low-cost medication can improve satisfaction rates and change the standard way the pain management is typically carried out for patients undergoing the knee replacement surgery.